The Gateway Hypothesis of substance abuse: Developmental, biological and societal perspectives

Acta Paediatrica, International Journal of Paediatrics

Volumn 104, Issue 2, 2015, Pages 130-137

  Kandel, Denise ^a,b,c   Kandel, Eric ^a  

^a Columbia University ^*  (United States)

^b New York State Psychiatric Institute ^*  (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Cocaine; E cigarettes; Gateway Hypothesis; Histone acetylation; Nicotine

Indexed keywords

COCAINE; ELECTRONIC CIGARETTE; ILLICIT DRUG; NICOTINE; DOPAMINE UPTAKE INHIBITOR; GANGLION STIMULATING AGENT;

ALCOHOL CONSUMPTION; BEHAVIOR; CANNABIS USE; CYTOLOGY; DRUG USE; EPIDEMIOLOGICAL DATA; HUMAN; HYPOTHESIS; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE; TOBACCO USE; ANIMAL; ANIMAL BEHAVIOR; CORPUS STRIATUM; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

ANIMALS; BEHAVIOR, ANIMAL; COCAINE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE UPTAKE INHIBITORS; GANGLIONIC STIMULANTS; HUMANS; NICOTINE; SUBSTANCE-RELATED DISORDERS;

EID: 84921607104     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12851     Document Type: Review

References (42)

1. Kandel DB,. Stages in adolescent involvement in drug use. Science 1975; 190: 912-4.
2. Levine AA, Huang YY, Drisaldi B, Griffin EA Jr, Pollak DD, Xu S, et al. Molecular mechanism for a Gateway Drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med 2011; 3: 107ra109.
3. Kandel ER, Kandel DB,. A molecular basis for nicotine as a Gateway Drug. N Engl J Med 2014; 371: 931-42.
4. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA), 2013.
5. Kandel DB, Yamaguchi K, Chen K,. Stages of progression in drug involvement from adolescence to adulthood. J Stud Alcohol 1992; 53: 447-67.
6. Wagner FA, Anthony JC,. Into the world of illegal drug use: exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana and cocaine. Am J Epidemiol 2002; 155: 918-25.
7. Kandel DB,. Stages and pathways of drug involvement: examining the Gateway Hypothesis, Cambridge. UK: Cambridge University Press, 2002.
8. Huizink AC, Levälathi E, Korhonen T, Dick DM, Pulkkinen L, Rose RJ, et al. Tobacco, cannabis, and other illicit drug use among Finnish adolescent twins: causal relationship or correlated liabilities? J Stud Alcohol Drugs 2010; 71: 5-14.
9. Fergusson D, Boden J, Horwood LJ,. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction 2006; 101: 556-66.
10. Degenhardt L, Dierker L, Chiu WT, Medina-Mora ME, Neymark Y, Sampson N, et al. Evaluating the drug use "gateway" theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health surveys. Drug Alcohol Depend 2010; 108: 84-97.
11. Palmer RHC, Button TM, Rhee SH, Corley RP, Young SE, Stallings MC, et al. Genetic etiology of the common liability to drug dependence: evidence of common and specific mechanisms for DSM-IV dependence symptoms. Drug Alcohol Depend 2012; 123S: S24-32.
12. Vanyukov MM, Tarter RE, Kririlova GP, Kirisci L, Reynolds MD, Kreek MJ, et al. Common liability to addiction and "gateway hypothesis": theoretical, empirical and evolutionary perspective. Drug Alcohol Depend 2012; 123 (Suppl 1): S3-17.
13. Morral AR, McCaffrey DF, Paddock SM,. Reassessing the marijuana gateway effect. Addiction 2002; 97: 1493-504.
14. Lynskey MT, Agrawal A, Henders A, Nelson EC, Madden PA, Martin NG,. An Australian twin study of cannabis and other illicit drug use and misuse, and other psychopathology. Twin Res Hum Genet 2012; 15: 631-41.
15. Agrawal A, Neale MC, Prescott CA, Kendler KS,. A twin study of early cannabis use and subsequent use and abuse/dependence of other illicit drugs. Psychol Med 2004; 34: 1227-37.
16. Verweij KJ, Zietsch BP, Lynskey MT, Medland SE, Neale MC, Martin NG, et al. Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies. Addiction 2010; 105: 417-30.
17. Lessem JM, Hopfer CJ, Haberstick BC, Timberlake D, Ehringer MA, Smolen A, et al. Relationship between adolescent marijuana use and young adult illicit drug use. Behav Genet 2006; 36: 498-506.
18. Wilcox HC, Wagner FA, Anthony JC,. Exposure opportunity as a mechanism linking youth marijuana use to hallucinogen use. Drug Alcohol Depend 2002; 66: 127-35.
19. Palmer RHC, Young SE, Hopfer CJ, Corley RP, Stallings MC, Crowley TJ, et al. Developmental epidemiology of drug use and abuse in adolescence and young adulthood: evidence of generalized risk. Drug Alcohol Depend 2009; 102: 78-87.
20. Cleveland HH, Wiebe RP,. Understanding the association between adolescent marijuana use and later serious drug use: gateway effect or developmental trajectory. Dev Psychopathol 2008; 20: 615-32.
21. Tarter RE, Vanyukov M, Kirisci L, Reynolds M, Clark DB,. Predictors of marijuana use in adolescents before and after licit drug use: examination of the Gateway Hypothesis. Am J Psychiatry 2006; 163: 2134-40.
22. Kendler KS, Myers J, Prescott CA,. Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence. Arch Gen Psychiatry 2007; 64: 1313-20.
23. Kandel D,. Does marijuana use cause the use of other drugs? JAMA 2003; 289: 482-3.
24. Kandel D, Yamaguchi K,. Testing the gateway hypothesis: an editorial. Addiction 2006; 101: 470-2.
25. Wikler A,. On the nature of addiction and habituation. Br J Addict Alcohol Other Drugs 1961; 57: 73-9.
26. Kandel ER,. The molecular biology of memory storage: a dialogue between genes and synapses. Science 2001; 294: 1030-8.
27. Hyman SE, Malenka RC, Nestler EJ,. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006; 29: 565-98.
28. Hiroi N, Brown J, Haile CN, Ye H, Greenberg ME, Nestler EJ,. FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci USA 1997; 94: 10397-402.
29. Levine AA, Guan Z, Barco A, Xu S, Kandel ER, Schwartz JH,. CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. PNAS 2005; 102: 19186-91.
30. Alibhai IN, Gree TA, Potashkin JA, Nestler EJ,. Regulation of fosB and ΔfosB mRNA expression: in vivo and in vitro studies. Brain Res 2007; 1143: 22-33.
31. Kandel DB, Logan JA,. Patterns of drug use from adolescence to young adulthood-I. Periods of risk for initiation, continued use, and discontinuation. Am J Public Health 1984; 74: 660-6.
32. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA,. Nicotine dependence and psychiatric disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004; 61: 1107-15.
33. Grana R, Benowitz N, Glantz S,. E-cigarettes: a scientific review. Circulation 2014; 129: 1972-86.
34. Frieden T,. E-cigarette use more than doubles among U.S. middle and high school students from 2011-2012. Centers for Disease Control (CDC), editor, 2013. Available from URL http://www.cdc.gov/media.releases/2013/p0905-ecigarette-use.html.
35. Bunnell R, Agaku I, Apelberg B, Caraballo R, King B, Arrazola R, et al. Intentions to smoke cigarettes among never-smoking US middle and high school electronic cigarette users, National Youth Tobacco Survey, 2011-2013. Nicotine Tob Res 2014; doi: 10.1093/ntr/ntu166. In press: 23 pgs.
36. Bhatnagar A, Whitsel LP, Ribisl KM, Bullen C, Chaloupka F, Piano MR, et al. Electronic cigarettes: a policy statement from the American Heart Association. Circulation 2014; 130: 1418-36.
37. World Health Organization. Electronic nicotine delivery systems, in Conference of the Parties to the WHO Framework Convention on Tobacco Control; 2014, July 21; WHO Framework Convention on Tobacco Control; 13 pgs. Available from URL http://apps.who.int/gb/fctc/PDF/cop6/FCTC-COP6-10-en.pdf?ua=1.
38. Grana R, Benowitz N, Glantz S,. Background paper on e-cigarettes, in Tobacco Control Paper Series; 2013, December; World Health Organization (WHO): University of California, San Francisco.
39. McQuown SC, Belluzzi JD, Leslie FM,. Low dose nicotine treatment during early adolescence increases subsequent cocaine reward. Neurotoxicol Teratol 2007; 29: 66-73.
40. McQuown SC, Dao JM, Belluzzi JD, Leslie FM,. Age-dependent effects of low-dose nicotine treatment on cocaine-induced behavioral plasticity in rats. Psychopharmacology 2009; 207: 143-52.
41. Kelley BM, Rowan JD,. Long-term, low-level adolescent nicotine exposure produces dose-dependent changes in cocaine sensitivity and reward in adult mice. Int J Devl Neurosci 2004; 22: 339-48.
42. Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE,. Monitoring the Future national results on adolescent drug use: overview of key findings, 2013; Ann Arbor, MI: Institute for Social Research, the University of Michigan, 2014.